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Purpose: Doubling the dose of antihypertensive drugs
is necessary to manage hypertension in patients whose
disease is uncontrolled. However, this strategy can result
in safety issues. This study compared the safety and
efﬁcacy of up-titration of the nifedipine gastrointestinal
therapeutic system (GITS) with up-titration of valsartan
monotherapy; these were also compared with low-dose
combinations of the two therapies.
Methods: This prospective, open-label, random-
ized, active-controlled, multicenter study lasted 8
weeks. If patients did not meet the target blood
pressure (BP) after 4 weeks of treatment with low-
dose monotherapy, they were randomized to up-
titration of the nifedipine GITS dose from 30 mg
(N30) to 60 mg or valsartan from 80 mg to 160 mg or
they were randomized to receive a low-dose combi-
nation of N30 and valsartan 80 mg for another 4
weeks. BP variability was assessed by using the SD or
the %CV of the short-term BP measured at clinic.832Findings: Of the 391 patients (20~70 years with
stage II or higher hypertension) screened for study
inclusion, 362 patients who had 3 BP measurements
were enrolled. The reduction in the mean systolic/
diastolic BP from baseline to week 4 was similar in
both low-dose monotherapy groups with either N30
or valsartan 80 mg. BP variability (SD) was un-
changed with either therapy, but the %CV was
slightly increased in the N30 group. There was no
signiﬁcant difference in BP variability either in SD or
%CV between responders and nonresponders to each
monotherapy despite the signiﬁcant difference in the
mean BP changes. The up-titration effect of nifedipine
GTS from 30 to 60 mg exhibited an additionalVolume 38 Number 4
J.B. Park et al.BP reduction, but this effect was not shown in the up-
titration of valsartan from 80 to 160 mg. Although the
difference in BP was obvious between high-dose nife-
dipine GTS and valsartan, the BP variability was
unchanged between the 2 drugs and was similar to
the low-dose combinations. There was a low rate of
adverse events in all treatment groups. In addition,
escalating the dose of either nifedipine GITS or valsar-
tan revealed a similar occurrence of adverse effects with
low-dose monotherapy or the low-dose combination.
Implications: Compared with up-titration of the
angiotensin receptor blocker valsartan, up-titration of
the calcium channel blocker nifedipine GITS provided
no additional increased safety concerns and revealed
better mean reductions in BP without affecting short-
term BP variability. ClinicalTrials.gov identiﬁer:
NCT01071122. (Clin Ther. 2016;38:832–842) & 2016
The Authors. Published by Elsevier HS Journals, Inc.
Key words: angiotensin receptor blocker, antihy-
pertensive agents, BP variability, calcium channel
blocker, hypertension, safety.
INTRODUCTION
Although hypertension is the most pervasive risk
factor for cardiovascular diseases, its control rate is
not very high. Many guidelines have been introduced
to increase the control rate.1,2 Except for special cases,
most of the guidelines suggest starting medication as
monotherapy and increasing the dose or prescribing a
low-dose combination. Studies show that the low-dose
combination is more effective than increasing the dose
of a single drug.3–5 In practice, however, only a few
studies have compared the antihypertensive effects
and adverse effects of switching angiotensin receptor
blockers (ARBs) and calcium channel blockers (CCBs)
from low to high doses; these agents are recommended
as primary drugs in most of the guidelines.6–8 In
addition, only a few studies have compared the
antihypertensive effects and adverse effects of high
doses of a single drug versus combination therapy.9,10
The previous FOCUS study6 found that, compared
with the combination of a high-dose nifedipine gastro-
intestinal therapeutic system (GITS) and valsartan, the
low-dose combination of nifedipine GITS plus valsar-
tan or high-dose nifedipine was more effective in
improving peripheral (brachial) hemodynamics,
thereby lowering central and peripheral blood pres-
sure (BP). However, few studies have shown theApril 2016effects of the low-dose combination on BP variability;
this variability is known to be related to cardiovas-
cular morbidity and mortality, independent from
mean BP and frequency of adverse effects caused by
powerful BP reductions produced by step-by-step
increases in dose.11,12
Although the average BP is adopted for treatment
decisions in a practical way, there is a wide ﬂuctua-
tion in BP, which changes with every beat. There-
fore, when there is too much difference between the
ﬁrst and second BP levels, the average BP is calcu-
lated by measuring it a third time and deriving the
mean value of the second and third measurements.
However, BP is also affected by sympathetic drive,
arterial or cardiopulmonary reﬂex, and arterial stiff-
ness. For the beat-to-beat BP variability, the sym-
pathetic nervous system and psychological factors
are considered crucial, as well as the difference
caused by depressed baroreﬂex function.13,14 Baror-
eﬂex dysfunction is caused by physical and emo-
tional stimuli and changes in respiration, as well as
rhythmic changes in the central autonomic drive.
Because short-term BP variability is determined by
various hemodynamics, independent from the mean
BP, the cardiovascular risks are increased; therefore,
its importance is being recognized in clinical settings.
A meta-analysis found that amlodipine, a CCB, has a
beneﬁcial effect on long-term BP variability.15 The
long-acting diuretic agents amlodipine and indapa-
mide were repeatedly found to reduce BP variability,
and their combination is expected to show better
effects.16
The CCBs exhibit very strong and dose-dependent
antihypertensive effects. However, a higher dose results
in more adverse effects, commonly peripheral edema,
which is a dose-limiting effect that restricts drug adher-
ence.4 Usually, it is recommended to use rational
combination with different mechanisms to improve BP
control and, if BP is not clinically controlled with low
doses, use of a drug combination is recommended rather
than an increase in dose because of the increase in
adverse effects. For ARBs, when their dose is increased,
the BP-lowering effect is relatively lower but is safe from
adverse effects, compared with other drugs. Thus, the 2
drugs vary in terms of adverse effects and efﬁcacy of up-
titration.
In the present multicenter, randomized, active-
controlled study, patients with stage II or higher
hypertension and patients who did not reach target833
Clinical TherapeuticsBP with an initial low dose of 2 agents were recruited.
We compared the safety and efﬁcacy of up-titration of
nifedipine GITS versus up-titration of valsartan mono-
therapy, which were compared with low-dose combi-
nations of the 2 therapies.
PATIENTS AND METHODS
This study was a national, prospective, open-label,
randomized, active-controlled trial. The antihyperten-
sive effects and adverse effects of high-dose nifedipine
GITS 60 mg (N60) or valsartan 160 mg (V160) versus
nifedipine GITS 30 mg plus valsartan 80 mg (N30 þ
V80) were compared in patients with higher than
moderate hypertension whose BP was inadequately
controlled by low-dose nifedipine GITS 30 mg (N30)
or low-dose valsartan 80 mg (V80) alone. Patients
were recruited from 17 study centers in South Korea
between March 2010 and February 2012. The study
protocol was approved by the institutional review
board of each center, and it was conducted in
accordance with the ethical principles of the Declara-
tion of Helsinki and Good Publication Practice guide-
lines. All of the patients provided written informed
consent before entry into the study.
Study Population
Eligible patients were aged 20 to 70 years with
stage II or higher hypertension (diastolic BP [DBP]
Z100 mm Hg and/or systolic BP [SBP] Z160 mm
Hg) and who were either treatment naive or had not
used an ARB or a CCB. There was no washout period.
Major exclusion criteria included severe hypertension
(DBP Z120 mm Hg and/or SBP Z200 mm Hg),
evidence of secondary hypertension, history of cardi-
ovascular or cerebrovascular disease within the pre-
vious 12 months, type 1 diabetes, chronic kidney
disease (serum creatinine level Z1.7 mg/dL), severe
gastrointestinal disease, hepatic and biliary disease, or
concomitant use of any cytochrome P-450 3A4 in-
hibitor or inducer.
Study Design
After an initial screening visit, all eligible patients
were randomized at baseline to receive N30 or V80.
After 4 weeks of treatment, patients who did not reach
the target BP of o140/90 mm Hg (o130/80 mm Hg
in patients with diabetes) were further randomized to
receive either N30 þ V80 or up-titration of mono-
therapy (N60 or V160) for 4 weeks. Low-dose834combination groups were drawn from both the N30
and V80 groups (28 patients from the N30 group and
38 patients from the V80 group). Patients meeting the
target BP remained on low-dose monotherapy for 4
weeks. Brachial SBP and DBP were measured by using
the Omron HEM-7080IT-E (Omron, Kyoto, Japan)
device at 3-minute intervals. Pulse pressure was
calculated as the difference between SBP and DBP.
Clinical BP variability was calculated as the short-term
BP variability; the SD of SBP was calculated 3 times at
1- to 2-minute intervals, and the %CV was calculated
by dividing the SD by the mean.
Statistical Analysis
Statistical analyses were performed by using SAS
version 9.1.3 (SAS Institute, Inc, Cary, North Caro-
lina). Data are presented as mean (SD), unless other-
wise speciﬁed. Baseline characteristics were compared
by using a 2-sample t test and Pearson’s χ2 test, as
appropriate. Changes were expressed as the difference
between week 4 and baseline and between week 8 and
week 4. The main comparisons were performed by
using ANCOVA with the covariates. The safety
analysis was conducted on all patients who had
taken at least 1 dose of the study drug. All of the tests
were bilateral using α ¼ 0.05; the exception was the
stepwise method, which was bilateral using α ¼ 0.15.RESULTS
Of the 391 subjects screened for inclusion, 362
subjects were randomized to receive low-dose mono-
therapy, including 181 patients for the N30 group and
181 patients for the V80 group for 4 weeks (Figure).
After 4 weeks, 203 patients who did not reach their
target BP level were randomized to receive up-titration
or the low-dose combination for additional 4 weeks.
Baseline Characteristics
As shown in Table I, there were no differences in
BP or demographic characteristics between the 2 low-
dose treatment groups.
Effects of Low-dose ARB or CCB on BP Variables
After 4 weeks, SBP/DBP were both signiﬁcantly
decreased by –21.1 (14.3)/–11.8 (8.9) mm Hg in the
N30 group and by –18.7 (15.9)/–10.5 (9.9) mm Hg in
the V80 group (both, Po 0.001) (Table II). When BP
variability was measured according to SD or %CV ofVolume 38 Number 4
Screening failure, n = 29
-Consent withrawn, n = 6
-Protocol violation, n = 23
Step 1
(Randomization, n = 362)
Premature termination, n = 23
-Adverse event, n = 12
-Noncompliant with study medication, n = 1
-Consent withdrawn, n = 7
-Protocol violation, n = 3
Premature termination, n = 10
-Adverse event, n = 2
-Noncompliant with study medication, n = 3
-Lost to follow-up, n = 1
-Protocol violation, n = 4
Premature termination, n = 3
-Adverse event, n = 2
-Noncompliant with study medication, n = 1
Step 2
Premature termination, n = 2
-Adverse event, n = 1
-Consent withdrawn, n = 1
Premature termination, n = 2
-Consen withdrawn, n = 1
-Lost to follow-up, n = 1
Screening
N = 391
n 30 mg
n = 181
V 80 mg
n = 181
Failing target BP
n = 96
Achieving target BP
n = 62
n 60 mg
n = 68
n 30 mg + V 80 mg
n = 66
n 30 mg
n = 28
V 80 mg
n = 38
Failing target BP
n = 107
V 160 mg
   n  = 69
Achieving target BP
n = 64
Group EGroup D
V 80 mg
n = 64
V 160 mg
n = 66
Group C
n 30 mg + V 80 mg
n = 66
Group B
n 60 mg
n = 66
Group A
n 30 mg
n = 60
Figure. Study design. After screening, the first randomization to low-dose monotherapy was performed with
either nifedipine (N) gastrointestinal therapeutic system (GITS) 30 mg or valsartan (V) 80 mg.
Patients not meeting the target blood pressure (BP) level (o140/90 mm Hg oro130/80 mm Hg for
those with diabetes) for 4 weeks underwent a second randomization to up-titration of monotherapy
or a low-dose combination for the remaining 4 weeks.
J.B. Park et al.SBP, there was no difference in the 2 low-dose groups,
and the BP response and control rate were similar. In
the nifedipine low-dose, 30-mg group, younger men
with higher triglyceride levels were more likely to be
nonresponders (Table III). However, in the valsartan
low-dose 80-mg group, men with a lower functioning
kidney were more likely to be nonresponders. Despite
the decrease in BP, neither group exhibited much
difference in short-term BP variability.Up-titration Effect of Nifedipine GTS and
Valsartan on BP Variables After an Additional
4 Weeks of Treatment
In the N60 group in which nifedipine was increased
from 30 mg (ie, low-dose nifedipine GTS and valsar-
tan group) in week 4 to 60 mg in week 8, an
additional BP decrease was recorded (from 149.7
[10.2] mm Hg to 138.5 [9.4] mm Hg; P o 0.01)
(Table IV). However, for the V160 group, in which
valsartan was increased from 80 to 160 mg, there was
no additional decrease in BP (from 149.9 [10.0] mm
Hg to 146.9 [15.6] mm Hg). For the nifedipine up-
titration group, BP decreased by –11.1 (11.6) mmApril 2016Hg and for the valsartan up-titration group, it was
decreased by –3.1 (13.4) mm Hg; the difference was
statistically signiﬁcant (P o 0.01). In the low-dose
combination group, there was a decrease in BP
from 151.1 (13.7) mm Hg to 136.5 (15.1) mm Hg
(P o 0.01). However, although there was an
obvious difference between the groups, there was no
difference in BP variability measured with SD or %CV
of SBP.Safety Variables
During the low-dose monotherapy phase, 70 ad-
verse effects were reported by 46 (25.4%) patients in
the N30 group and 41 AEs reported by 32 (17.7%)
patients in the V80 group, including 12.7% and 3.9%
of patients in the respective groups who had poten-
tially treatment-related AEs (Table V). During the
low-dose combination and high-dose monotherapy
phase, 7 (10.6%) patients experienced 7 AEs in the
N30 þ V80 group, 7 (10.5%) patients experienced 9
AEs in the N60 group (1 serious event of muscle
strain, unrelated to the study drug), and 11 (16.2%)
patients experienced 16 AEs in the V160 group.835
Table I. Baseline characteristics of the first randomization with low-dose nifedipine 30 mg versus valsartan
80 mg. Unless otherwise indicated, values are given as mean (SD).
Characteristic
Nifedipine 30 mg
(n ¼ 181)
Valsartan 80 mg
(n ¼ 181) P
Male sex, no. (%) 117 (64.6) 114 (63.0) 0.7428
Age, y 48.2 (10.2) 49.4 (9.5) 0.2640
Weight, kg 71.7 (12.9) 71.2 (13.6 0.7230
Height, cm 167.2 (9.0) 165.4 (9.1) 0.0614
Body mass index, kg/m2 25.5 (3.3) 25.9 (3.7) 0.3228
Duration of hypertension, y 2.5 (4.3) 2.6 (5.2) 0.8478
Dyslipidemia 23 (12.7) 20 (11.1) 0.6260
Diabetes mellitus 11 (6.1) 9 (5.0) 0.6454
Hematocrit, % 41.6 (2.6) 41.4 (2.6) 0.6559
Fasting glucose, mg/dL 106.8 (26.2) 106.4 (19.6) 0.8901
Total cholesterol, mg/dL 223.9 (36.4) 225.6 (35.6) 0.6581
HDL-C, mg/dL 44.6 (21.8) 43.8 (23.5) 0.7202
Triglyceride, mg/dL 147.1 (118.4) 157.4 (171.4) 0.5072
LDL-C, mg/dL 93.2 (55.5) 96.1 (55.8) 0.6164
Serum creatinine, mg/dL 0.9 (0.2) 0.9 (0.3) 0.8813
Baseline bBP
bSBP, mm Hg 162.6 (11.8 161 (10.7) 0.1577
bDBP, mm Hg 102.4 (8.4) 101 (8.9) 0.1124
bPP, mm Hg 60.2 (12.7) 60 (13.1) 0.8679
bHR, beats/min 73.5 (10.8) 74.1 (10.8) 0.5758
Previous antihypertensive treatments 32 (17.7) 35 (19.3) 0.6847
bBP ¼ brachial blood pressure; bDBP ¼ brachial diastolic blood pressure; bHR ¼ brachial heart rate; bPP ¼ brachial pulse
pressure; bSBP ¼ brachial systolic blood pressure.
Clinical TherapeuticsPotential treatment-related AEs occurred in 1.5%,
4.5%, and 5.8% of patients in the N30 þ V80,
N60, and V160 groups, respectively. Most of the
AEs were mild to moderate in intensity.DISCUSSION
This prospective, open-label, randomized, active-
controlled 8-week study explored the safety and
efﬁcacy of up-titration of nifedipine GITS versus
up-titration of valsartan monotherapy. In addition to
the previous FOCUS study that reported an increasing
average central and peripheral BP reduction by dou-
bling the dose of nifedipine GITS,6 the present study is
the ﬁrst to focus on safety by using a stepwise up-
titration of nifedipine GITS and BP variability, known836to be an independent predictor of cardiovascular
mortality. The main ﬁndings of the study, compared
with up-titration of the ARB valsartan, are as follows:
(1) up-titration of the CCB nifedipine GITS produced
no additional increased safety concerns; and (2) despite
better BP reduction, up-titration of the CCB nifedipine
GITS produced no change in short-term BP variability.
BP Variability and Drug Treatment
Among the major classes of antihypertensive drugs,
only CCBs lowered the BP variability by using the SD
of 24-hour BP monitoring.13,16–18 A large BP varia-
bility is expected if BP is drastically reduced; thus, this
CCB effect disappears when the BP variability is
calculated as the %CV, which is SD divided by the
mean BP.13,16,17 SD is preferred over %CV for theVolume 38 Number 4
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April 2016assessment of BP variability for 2 reasons. First, it is
invalid to calculate the reduction in BP variability
independent of BP level with a robust division as using
%CV because some statistical efﬁcacy may be lost.16
In addition, although prognostic value concerning the
%CV of BP is limited in the literature, the SD of 24-
hour BP has been frequently reported in various
studies on cardiovascular morbidity and mortality.
In the present study, there was no difference in the
SD or %CV BP variability between the 2 low-dose
groups (ie, the responder and nonresponder groups).
Therefore, although there is a substantial decrease in
BP, it is assumed that short-term BP variability is not
always large. A large BP variability is due to the
combination of a person’s activities, psychological
factors, drug compliance, sympathetic nerve system,
and humoral systems. Other than short-term BP
variability, there are various forms of BP variability
such as mid-term (day-by-day) and long-term (visit-to-
visit).19 For now, long-term BP variability is believed
to be related more to prognosis than to other varia-
bilities.12,20,21 There is currently no standard measure-
ment for BP variability.22
The effectiveness of a drug in reducing BP varia-
bility is known to be inﬂuenced by age, mean BP, and
heart rate. CCBs are apparently effective in BP
variability because there was much reduction in the
average BP.13,16,23 In this study, although high-dose
nifedipine GITS had a much better BP-lowering effect
than high-dose valsartan, they had no difference in the
SD and %CV of BP due to the difference in mecha-
nisms between the BP variability and beat-to-beat BP
variability shown in 24-hour BP. It may signify that its
effects cannot be revealed within a short study period
(ie, 8 weeks), and we therefore assumed no effect of it.
Further studies with lengthier study periods of longer
BP variability will be necessary.
Safety of Up-titration of CCBs
A previous study found that, although the BP-
lowering effect of both amlodipine and nifedipine
(the high-dose CCBs) was evident compared with
low doses of the CCBs, edema was found to occur
25% and 15% more in the amlodipine and nifedipine
groups, respectively, than in the low-dose amlodipine
or nifedipine monotherapy group or the low-dose
combination group.9 In the present study, after 4
weeks of N30 treatment, the dose was increased to
60 mg (N60) for those who did not meet the target837
Table III. Responders versus nonresponders after treatment with a low dose of nifedipine gastrointestinal
therapeutic system or valsartan for 4 weeks. Unless otherwise indicated, values are given as mean
(SD); “changes” indicate changes from baseline to week 4.
Characteristic
Nifedipine 30 mg (N ¼ 177*) Valsartan 80 mg (N ¼ 181)
Responders
(n ¼ 119)
Nonresponders
(n ¼ 58)
P
Responders
(n ¼ 117)
Nonresponders
(n ¼ 64)
P4 Weeks 4 Weeks 4 Weeks 4 Weeks
Male sex, no. (%) 70 (58.8) 44 (75.9) 0.0263 67(57.3) 47 (73.4) 0.0312
Age, y 49.7 (10.1) 45.4 (9.9) 0.0089 49.3 (10.1) 49.5 (8.5) 0.9276
Weight, kg 70.5 (13.7) 73.9 (10.9) 0.1005 70.2 (13.2) 73.0 (14.4) 0.1884
Height, cm 166.3 (9.5) 168.5 (7.7) 0.1185 164.7 (9.1) 166.7 (9.1) 0.1763
Body mass index, kg/m2 25.3 (3.3) 26.0 (3.2) 0.2254 25.8 (3.6) 26.2 (3.8) 0.4777
Duration of hypertension, y 2.6 (4.6) 2.3 (3.8) 0.6982 2.4 (5.7) 2.8 (4.3) 0.5592
Dyslipidemia 19 (16.0) 3 (5.2) 0.0410 14 (12.0) 6 (9.4) 0.5950
Diabetes mellitus 5 (4.2) 5 (8.6) 0.2995 7 (6.0) 2 (3.1) 0.4956
Hematocrit, % 41.6 (2.5) 41.6 (2.6) 0.9718 41.4 (2.5) 41.5 (2.7) 0.8255
Fasting glucose, mg/dL 106.7 (28.7) 107.1 (20.5) 0.9212 105.1 (15.9) 109.0 (25.3) 0.3023
Total cholesterol, mg/dL 222.7 (35.7) 224.7 (36.4) 0.7243 226.1 (35.6) 224.7 (35.8) 0.8076
HDL-C, mg/dL 45.2 ( 23.7) 43.1 (17.8) 0.5139 43.7 (23.6) 43.8 (23.5) 0.9839
Triglyceride, mg/dL 131.6 (96.1) 179.2 (151.9) 0.0320 160.5 (205.0) 151.6 (80.7) 0.6783
LDL-C, mg/dL 94.5 (56.1) 89.4 (55.6) 0.5718 95.9 (59.1) 96.6 (49.7) 0.9368
Serum creatinine, mg/dL 0.9 (0.2) 0.9 (0.2) 0.8179 0.8 (0.3) 0.9 (0.2) 0.0054
Baseline bBP
Changes in bSBP, mm Hg –27.4 (11.6) –8.2 (9.8) o0.0001 –26.6 (11.4) –4.1 (12.2) o0.0001
Changes in bDBP, mm Hg –15.9 (6.1) –3.2 (7.5) o0.0001 –15.7 (6.7) –0.9 (7.2) o0.0001
Changes in bPP, mm Hg –11.5 (9.8) –5.0 (12.8) o0.0001 –10.9 (10.6) –3.2 (10.8) o0.0001
Changes in bHR, beats/min 2.4 (9.2) 2.5 (10.3) 0.9437 0.4 (10.0) –0.5 (8.8) 0.6687
Blood pressure variability
Changes in SD of clinical
SBP
0.13 (3.08) 0.29 (3.22) 0.2352 –0.37 (3.42) 0.52 (3.86) 0.0540
Changes in %CV of clinical SBP 0.54 (1.99) 0.30 (2.10) 0.9962 0.23 (2.28) 0.41 (2.47) 0.4752
Responder rate, % 119 (100.0) 0 0.0001 117 (100.0) 0 o0.0001
Control rate, % 62 (52.1) 2 (3.5) o0.0001 67 (57.3) 1 (1.6) o0.0001
bBP ¼ brachial blood pressure; bDBP ¼ brachial diastolic blood pressure; bHR ¼ brachial heart rate; bPP ¼ brachial pulse
pressure; bSBP ¼ brachial systolic blood pressure.
*4 people were excluded due to inaccurate evaluation of responsiveness.
Clinical TherapeuticsBP, and vasodilatory symptoms such as dizziness,
headache, ﬂushing, and palpitation were similar
between the treatment groups of 30 and 60 mg. In
addition, there was no difference between high-dose
valsartan and the low-dose combination of the
2 drugs.9 It is difﬁcult to explain why there was no
increase in the occurrence of adverse effects with N60,838which is known to have one of the strongest
vasodilation effects among CCBs. Compared with
low-dose valsartan, low-dose nifedipine had a higher
rate of adverse effects, and it can be assumed that the
occurrence of these effects did not increase as the dose
increased because the patients were adapting to low-
dose nifedipine.Volume 38 Number 4
Table IV. Further changes in blood pressure (BP) and BP parameters from 4 to 8 weeks in patients with controlled and uncontrolled disease.
Unless otherwise indicated, values are given as mean (SD).
Variable
Group A Group B Group C Group D Group E
Nifedipine 30 mg to
430 mg (n ¼ 60)
Nifedipine 30 mg to
460 mg (n ¼ 66)
Nifedipine 30 mg þ
Valsartan 80 mg (n ¼ 66)
Valsartan 80 mg to
4160 mg (n ¼ 66)
Valsartan 80 mg
480 mg (n ¼ 64)
4 Weeks 8 Weeks 4 Weeks 8 Weeks 4 Weeks 8 Weeks 4 Weeks 8 Weeks 4 Weeks 8 Weeks
Brachial BP, mm Hg
SBP 128.7 (7.5) 130.9 (10.4) 149.7 (10.2) 138.5 (9.4)* 151.1 (13.7) 136.5 (15.1)* 149.9 (10.0) 146.9 (15.6) 126.7 (7.0) 128.7 (12.6)
DBP 81.9 (5.9) 83.2 (8.1) 95.7 (8.3) 89.6 (9.4)* 95.3 (9.6) 86.8 (9.4)* 96.5 (9.5) 94.1 (11.3)† 80.6 (7.5) 81.8 (10.1)
HR, beats/min 74.3 (8.6) 70.2 (8.9)* 76.6 (10.1) 75.5 (11.4) 75.8 (10.1) 75.3 (10.5) 73.5 (11.2) 71.1 (9.4) 75.4 (10.9) 70.3 (9.7)*
BP variability
SD of SBP 3.59 (2.03) 3.10 (1.78) 4.17 (2.71) 3.81 (2.64) 4.00 (2.62) 3.72 (2.74) 4.21 (2.21) 3.69 (2.13) 3.55 (2.53) 3.78 (2.18)
%CV of SBP 2.78 (1.57) 2.37 (1.33) 2.78 (1.75) 2.76 (1.91) 2.65 (1.70) 2.69 (1.91) 2.80 (1.44) 2.54 (1.52) 2.8 (1.92) 2.92 (1.56)
Responder rate, % 58 (96.7) 54 (90.0) 34 (51.5) 52 (78.8) 31 (47.0) 56 (84.9) 30 (45.5) 37 (56.1) 63 (98.4) 58 (90.6)
Control rate, % 59 (98.3) 47 (78.3) 0 26 (39.4) 0 34 (51.5) 0 16 (24.2) 64 (100) 46 (71.9)
DBP ¼ diastolic BP; HR ¼ heart rate; SBP ¼ systolic BP.
*P o 0.01 versus 4 weeks.
†P o 0.05 versus 4 weeks.
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Table V. Number and percentage of patients with any emergent adverse event (given in brackets) during
treatment with the study drug (safety population). The most common emergent adverse events are
also presented (frequency Z2 patients in any group).
Weeks 1–4
Nifedipine 30 mg
(n ¼ 181)
Valsartan 80 mg
(n ¼ 181)
All emergent adverse events 46 (25.4) [70] 32 (17.7) [41]
Palpitations 1 (0.6) [1] 2 (1.1) [2]
Constipation 3 (1.7) [3] 1 (0.6) [1]
Gastroesophageal reﬂux 2 (1.1) [2] 0 (0.0) [0]
Nausea 3 (1.7) [3] 2 (1.1) [2]
Peripheral edema 2 (1.1) [2] 0 [0]
Cystitis 2 (1.1) [2] 0 [0]
Nasopharyngitis 2 (1.1) [2] 2 (1.1) [2]
Dyslipidemia 0 [0] 2 (1.1) [2]
Dizziness 3 (1.7) [3] 2 (1.1) [2]
Headache 16 (8.8) [19] 8 (4.4) [8]
Hypoesthesia 1 (0.6) [1] 2 (1.1) [2]
Flushing 3 (1.7) [3] 0 [0]
Hot ﬂush 5 (2.8) [5] 0 [0]
Serious adverse events 1 (0.6) [2] 1 (0.6) [1]
Drug-related adverse events 23 (12.7) [38] 7 (3.9) [10]
Weeks 5–8
Nifedipine 30 mg þ
Valsartan 80 mg (n ¼ 66)
Nifedipine 60 mg
(n ¼ 67)
Valsartan
160 mg (n ¼ 68)
All emergent adverse events 7 (10.6) [7] 7 (10.5) [9] 11 (16.2) [16]
Upper abdominal pain 0 [0] 0 [0] 2 (2.9) [2]
Peripheral edema 0 [0] 2 (3.0) [2] 0 [0]
Nasopharyngitis 2 (3.0) [2] 0 [0] 2 (2.9) [2]
Headache 1 (1.5) [1] 3 (4.5) [3] 1 (1.5) [1]
Serious adverse events 0 [0] 1 (1.5) [1] 0 [0]
Drug-related adverse events 1 (1.5) [1] 3 (4.5) [4] 4 (5.8) [5]
Clinical TherapeuticsStudy Limitations
One of the limitations of the study was the
signiﬁcant difference in BP reduction between the
N60 group and the V160 group. The cause may be
that BP variability was more prominent with high BP,
although the SD and %CV of BP did not differ
between the 2 treatments in this study. In terms of
clinical practice, BP ﬂuctuation can differ occasionally;
thus, in addition to short-term BP variability in this
study, additional studies should be performed, includ-
ing monitoring of the long-term (visit-to-visit) BP
variability, which is more related to cardiovascular
risk. Second, this study did no answer why there was
no difference in BP variability between the 2 groups.
Because short-term BP variability and heart rate840variability are both largely affected by the sympathetic
nerve system, additional studies on the system are
necessary. Third, the research period was relatively
short, and the number of participating patients was
limited. Clinical studies are therefore needed with a
larger cohort of patients, a longer study period, and
diverse BP variability parameters.CONCLUSIONS
Up-titration of nifedipine GITS led to no additional
safety concerns compared with up-titration of valsar-
tan or the low-dose combination of the 2, despite
strong reductions in BP in these study patients. There
was no further change in short-term BP variability.Volume 38 Number 4
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